Granted Patent B2

US 12,496,384 · App. 18/542,545 · Granted Dec 16, 2025

Inventors: Jeffrey Testani (Guilford, CT); Christopher McIntyre (Ontario, CA); Ian Crosbie (London, GB); Oliver Goedje (Strasslach, DE)

Assignee: DSRCo BV

A61M1/282A61F7/08A61K9/0019A61K9/08A61K31/7004A61K31/716A61K33/14A61M1/28A61M1/285A61M1/287A61M27/002A61M31/002A61P7/08A61L2/0047A61L2202/21A61M2205/18A61M2205/3317A61M2205/3337A61M2205/3344A61M2205/3368A61M2205/3379A61M2205/3569A61M2205/3576A61M2205/502A61M2205/52A61M2205/587A61M2205/6009A61M2205/70A61M2205/8206A61M2205/8243A61M2209/086A61M2209/088A61M2210/1017A61M2210/1085

Abstract

Claims (28)

1 . A direct sodium removal (DSR) infusate, comprising:

(a) a sodium concentration equal to or less than 35 meq/L;

(b) 10 grams of dextrose per 100 mL of aqueous solution, and

(c) 15 to 30 grams of icodextrin per 100 mL of aqueous solution.

2 . The DSR infusate of claim 1 , wherein the infusate has an osmolality and sodium concentration selected to induce a steep sodium gradient between a patient's blood serum sodium level and the infusate when instilled into the patient's peritoneal cavity during a first dwell period.

3 . The DSR infusate of claim 1 , wherein the infusate has an osmolality and sodium concentration selected to induce a shallow sodium gradient between a patient's blood serum sodium level and the infusate when instilled into the patient's peritoneal cavity during a second dwell period.

4 . The DSR infusate of claim 1 , wherein the infusate is sodium-free.

5 . The DSR infusate of claim 1 , wherein the infusate further comprises water.

6 . The DSR infusate of claim 1 , wherein the infusate comprises 15 grams of icodextrin per 100 mL of aqueous solution.

7 . The DSR infusate of claim 1 , wherein the infusate further comprises 0.5 to 50 grams of a high molecular weight biocompatible polymer having an average molecular weight greater than 10,000 Daltons per 100 mL of aqueous solution.

8 . The DSR infusate of claim 1 , wherein the infusate further comprises solutions containing any one or more of 0.5 to 50 grams of xylitol, glycerol, hyperbranched polyglycerol, sorbitol, carnitine, taurine, amino acids, urea, polyacrylate, polyethyleneimine, or stevioside per 100 mL of aqueous solution.

9 . The DSR infusate of claim 1 , wherein the infusate further comprises an electrolyte selected from among a magnesium salt and a calcium salt.

10 . The DSR infusate of claim 9 , wherein the infusate is formulated to be administered to a patient in need thereof to treat fluid overload, heart failure, or severe renal dysfunction of the patient.

11 . The DSR infusate of claim 1 , wherein the infusate further comprises at least one of an antimicrobial agent, an antifungal agent, or a buffering agent.

12 . The DSR infusate of claim 1 , wherein the infusate removes excess sodium to cause a reduction in fluid overload in a patient while maintaining a serum sodium level substantially unchanged.

13 . The DSR infusate of claim 1 , wherein the infusate is formulated to be administered by infusion into, and removal from, a peritoneal cavity of a patient.

14 . The DSR infusate of claim 13 , wherein the infusate is formulated to be sufficiently nonviscous that the infusate may be instilled into the peritoneal cavity from a reservoir via gravity feed.

15 . The DSR infusate of claim 13 , wherein the infusate is formulated to be instilled into the peritoneal cavity in an amount between 0.25 liter and 2.0 liter per DSR session.

16 . A method of removing excess sodium and fluid from a patient, the method comprising: administering the DSR infusate of any one of claims 1-15 into a peritoneal cavity of a patient to induce sodium and osmotic ultrafiltrate to accumulate with the infusate in the peritoneal cavity during a first dwell period; and removing the infusate, sodium and osmotic ultrafiltrate from the peritoneal cavity of the patient after the first dwell period.

17 . The method of claim 16 , further comprising:

administering the infusate into the peritoneal cavity of the patient to induce sodium and osmotic ultrafiltrate to accumulate with the infusate in the peritoneal cavity during a second dwell period; and

removing the infusate, sodium and osmotic ultrafiltrate from the peritoneal cavity of the patient after the second dwell period.

18 . The method of claim 16 , wherein the infusate is administered to the patient in need thereof for treating heart failure.

19 . The method of claim 16 , wherein the infusate is administered to the patient in need thereof for treating renal dysfunction.

20 . The method of claim 16 , wherein administering the infusate comprises instilling into the patient's peritoneal cavity an amount between 0.25 liter and 2.0 liter of fluid per DSR session.

21 . The method of claim 16 , the method further comprising, between administrations of the infusate, adjusting a serum sodium level of the patient by conducting hemodialysis or peritoneal dialysis.

22 . The method of claim 16 , wherein administering the infusate comprises introducing the infusate via a subcutaneous port or a conventional peritoneal dialysis catheter.

23 . The method of claim 16 , wherein the method further comprises monitoring a serum level of the patient during the first dwell period.

Assignments (3)

Continuity (6)

References Cited (400)